Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02013687Phase 1Completed

Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults

Role: lead

NCT01177202Phase 1Completed

Study of the Safety and Immunogenicity of H1N1 Vaccine

Role: lead

NCT02239172Phase 1Completed

PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine

Role: lead

NCT01250795Phase 1Completed

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

Role: lead

All 4 trials loaded